Scientific Affairs Group

Ellipses Pharma is privileged to be able to work with many of the leading minds as part of our Scientific Affairs Group.
A sample of these distinguished oncologists is set out below.

Professor Giuseppe Curigliano, MD, PhD

Giuseppe Curigliano, MD, PhD, is the Head of the Division of Early Drug Development at European Institute of Oncology, and Associate Professor of Medical Oncology and University of Milano, Italy. He is a clinician and researcher specializing in early drug development for patients with solid tumors with a special commitment on breast cancer.

He is also involved in translational research related to immunotherapy, precision medicine, and biomarker identification. He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG) Immune Task Force. He is founding member of/and scientific chair for the International Cardio-Oncology Society (ICOS). Dr Curigliano is a member of the ESMO Press & Media Affairs Committee from 2015 and he is serving on the ESMO Women for Oncology, ESMO Membership and ESMO Global Policy Commitees since 2016. He has contributed to over 280 peer-reviewed publications. He also serves on the European School of Oncology (ESO) faculty committee.

He has been appointed as Editor of Annals of Oncology for the period 2014-2018, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of European Journal of Cancer, editor of the Journal of Clinical Oncology. He has been awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017.

Professor Lex Eggermont, MD, PhD

Dr Alexander (Lex) Eggermont is the Director General of Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.

He is Professor of Oncology at the University Paris-Sud, Professor of Surgical Oncology and Professor of International Networking in Cancer Research at the Erasmus University Medical Centre in Rotterdam, the Netherlands. He obtained his PhD thesis in tumor immunology and is a fellow of the NCI Surgery Branch (Head Steven Rosenberg).

Professor Eggermont is a past President of ECCO and the EORTC and past Chair of the EORTC Melanoma Group. He is acting President of the European Academy of Cancer Sciences (2010–2018), Chair of the Board of Directors of Cancer Core Europe, and is Chair of the International Jury for Comprehensive Cancer Centre Program in Germany.

He (co)authored more than 700 peer reviewed publications and is Editor in Chief of the European Journal of Cancer.

Dr Giuseppe Giaccone, MD, PhD

Giuseppe Giaccone, MD, PhD, is associate director for clinical research and co-leader of the Experimental Therapeutics Program at the Lombardi Comprehensive Cancer Center, and the director for clinical research for the MedStar Georgetown Cancer Network.  He also serves as a professor of medical oncology and pharmacology in the Department of Oncology at Georgetown University Medical Center. Before coming to Lombardi, Dr. Giaccone was chief of the Medical Oncology Branch at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Dr. Giaccone is an internationally recognised expert in the field of lung cancer and developmental therapeutics, helping to develop new chemotherapies and new strategies of anticancer treatment, in particular with targeted agents that work specifically on cancer cells. Dr. Giaccone has published more than 500 peer-reviewed papers and contributed to more than 30 book chapters. He also has organised international conferences and serves as co-chair for the American Society for Clinical Oncology’s guidelines for advanced non-small cell lung cancer.

Professor Alberto Mantovani, MD, PhD

Dr Alberto Mantovani is an Italian physician and immunologist. He is Scientific Director of Istituto Clinico Humanitas (Humanitas Clinical and Research Center), President and Founder of the Fondazione Humanitas per la Ricerca, and Professor of Pathology at the State University of Milan.  He is known for his works in the roles of the immune system in the development of cancer. He identified molecules and paradigms related to innate immunity, inflammation and cancer including his research on tumor-associated macrophages (TAM, an acronym he coined) which established inflammation as one of the causes of cancer. He was the first to identify monocyte chemotactic protein – 1 / CCL2 in 1983, and PTX3 in 1997. His works revealed the existence of decoy receptors in cell-signalling. He has been the most cited scientist in Italy, and one of the ten most cited immunologists worldwide.

Professor Ruth Plummer, MD, PhD

Ruth Plummer is Professor of Experimental Cancer Medicine at the Northern Institute for Cancer Research, Newcastle University and an honorary consultant medical oncologist in Newcastle Hospitals NHS Foundation Trust.  She is Director of the Sir Bobby Robson Cancer Trials Research Centre within the Northern Centre for Cancer Care, which is a dedicated clinical trials unit based within the regional cancer centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre.  She trained at Cambridge and Oxford before moving back home to Newcastle and settling with her family in the Tyne valley.

Her clinical practice involves leading on the systemic therapies for skin cancer, with a portfolio of trials across all phases of drug development.  In addition she runs a phase I all-comers practice, taking responsibility for one of the most active phase I unit’s in the UK.

Her research interests are in the field of DNA repair and early phase clinical trials of novel agents, taking the first in class PARP inhibitor into the clinic in 2003, ATR inhibitor in 2012 and MCT1 inhibitor in 2014.

This research is either based in the Sir Bobby Robson Cancer Trials Research Centre or in the Northern Institute for Cancer Research of which she is a deputy director.  Nationally she chairs the Cancer Research UK New Agents Committee and sits as a member of Cancer Research UK’s Clinical Research Committee and until recently Science Committee.  She is a member of the MRC Stratified Medicine Group.

Dr Paul Richardson, MD

Paul Richardson MD is based at Dana Farber Cancer Institute where he is currently Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center.  He joined the Division of Hematologic Oncology and the Jerome Lipper Multiple Myeloma Center in December 1999, was appointed Clinical Director of the Myeloma Center in January 2001 and has since led several novel, biologically-derived translational efforts in multiple myeloma under the overall direction and mentorship of Kenneth Anderson, M.D. These have been focused in the clinical study of new drugs in the Phase 1, 2 and 3 settings as principal investigator and first author of derived manuscripts.

He is currently leading multiple efforts studying the use of combination therapies predominantly in relapsed and refractory myeloma.  He also serves as a principal investigator and study chairman for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity.   As a clinical researcher in myeloma and transplant, he has published 200 original articles and over 90 reviews, chapters, and editorials in peer-reviewed journals.

Dr Frances Shepherd, MD, PhD

Dr Shepherd is based out of the Princess Margaret Cancer Centre, UHN, Toronto and her contribution to the development and conduct of clinical trials is recognized internationally. She was the President of the International Association for the Study of Lung Cancer from 2005-2007. She was a member of the US National Institutes of Health Concept Evaluation Panel for Lung Cancer clinical trials. This body of CTEP (the Cancer Treatment Evaluation Program of the US NCI) was responsible for evaluating and approving all multi-center lung cancer clinical research studies submitted by the large US cooperative groups.

Currently, she sits on the Board of Directors of the American Society of Clinical Oncology and the European Organization for Research and Treatment of Cancer. She also Chairs the European Organization for Research and Treatment of Cancer Protocol Review committee. Dr Shepherd has served as Chair of the American Society of Clinical Oncology Membership and Publications Committees.

Dr Shepherd has designed and led more than 100 clinical trials over the past three decades, and her studies have changed treatment and outcomes for lung cancer patients at a global level.  She has authored or co-authored more than 450 peer reviewed publications and 35 book chapters.

Professor Patrick Schöffski, MD, MPH

Patrick Schöffski, MD, MPH, is a board-certified specialist for internal medicine, hematology and medical oncology originating from Hannover, Germany, where he also received a master’s degree in public health at Hannover Medical School.

He is the head of the Department of General Medical Oncology at the University Hospitals Leuven and also leads the Laboratory of Experimental Oncology at KU Leuven, Belgium. He is the current, re-elected Secretary-General of the Executive Committee and Board of the European Organisation for Research and Treatment of Cancer (EORTC). He was also part of the Board of Directors of the European Cancer Organisation (ECCO) and the Connective Tissue Oncology Society (CTOS) and is a current member of many scientific societies including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), German Society of Hematology and Oncology (DGHO), Belgian Society for Medical Oncology (BSMO), Japanese Society of Medical Oncology, Connective Tissue Oncology Society (CTOS) and the Histiocyte Society. In 2013 he was appointed member of the Belgian Royal Academy of Medicine.

Schöffski’s main clinical interest is the treatment of solid tumors and lymphomas. He is involved in a large number of prospective clinical trials in various tumor types, including orphan malignancies, ranging from phase 0-III. He leads an active phase I-team in Leuven, has a strong interest in multitumor phase II-screening studies, runs complex clinical trials in the field of personalized oncology and registration studies in various malignancies. He coordinates translational research projects associated with new drug development and in diseases such as sarcoma, urogenital and endocrine malignancies, and others. He has been involved in registration trials of antineoplastic agents in a variety of solid tumors. Prof. Schöffski has a strong background in clinical trial methodology. His Laboratory of Experimental Oncology at KU Leuven has a focus on mesenchymal malignancies and has established multiple cell line- or patient-derived xenograft models of soft tissue sarcomas and gastrointestinal stromal tumors, that are used for early drug screening and studies on cancer biology. This laboratory work has been the rationale for a number of ongoing and completed clinical trials.

He was work package leader in the Connective Tissue Cancers Network (CONTICANET), a Network of Excellence funded by the European Commission’s Sixth Framework Programme. He is member of the new EURACAN network for rare malignancies in Europe. Professor Schöffski has published >270 papers in international peer-reviewed oncology journals. He is member of the advisory board of several pharmaceutical and biotech companies and is an independent advisor to academic organisations such as Cancéropôle Île-de-France, Paris, France, the Ontario Institute for Cancer Research, Toronto, Canada, and the Cancer Center of Helsinki University Central Hospital. Until 2014 he acted as scientific chair of the Methods in Clinical Cancer Research Workshop series in Flims, Switzerland, organised by AACR, ECCO, ESMO and EORTC, and is currently involved in multiple educational activities in oncology on an international level. Based on his methodological and clinical research expertise, Prof. Schöffski is member of (or coordinates) a number of Independent Data Monitoring Committees for ongoing and completed Phase II/III clinical trials in collaboration with academic groups, biotech companies, clinical research organisations and pharmaceutical companies.